Investor Presentaiton
Targeted clinical development strategy
Target the large
US market for
first product
approvals
Advance
diagnostics to
market first
Develop
products for
both rare and
large
indications with
high unmet
needs
Focus on high
quality clinical
sites and
experienced
investigators
Position
products to
maximise
opportunity in
current
treatment
paradigms
Reinvest revenues to
part fund the
continued
development of the
therapeutics
US FDA Regulatory Engagement
Scope to expand into
others leveraging the
SAR Technology
✓ Three open Investigational New Drug (IND) to proceed clinical trials in the US
✓ Two Rare Pediatric Disease designations (RPDDs) from the US FDA
✓ Two Orphan Drug Designations (ODDS) from the FDA
CLARITY
2014 MILE
8View entire presentation